Last updated: February 4, 2026
Summary
OGESTREL 0.5/50-28 is a combined oral contraceptive (COC) marketed primarily in Brazil. Its positioning in the contraceptive market depends on its formulation, market penetration, regulatory environment, and competitive landscape. The drug combines ethinylestradiol (0.5 mg) and desogestrel (50 mcg) and is marketed under a 28-day cycle.
Market Overview
The global contraceptive market is characterized by steady growth driven by increasing demand for family planning methods, rising awareness, and evolving regulatory policies. Latin America, particularly Brazil, accounts for a significant segment due to high population density and established pharmaceutical infrastructure.
In 2022, the global contraceptive market was valued at approximately USD 22.4 billion and is projected to grow at a CAGR of 5% through 2030. Brazil holds an estimated 6-8% share of this market.[1]
Regulatory and Patent Landscape
OGESTREL 0.5/50-28 has been on the market for over 10 years in Brazil. It is approved by the Agência Nacional de Vigilância Sanitária (ANVISA). The product's patent protection has expired in most jurisdictions, though local regulatory data may provide barriers to entry for generic competitors.
Patents related to the specific formulation and delivery system expired in the early 2010s. No recent patent filings or exclusivity periods are currently active, creating an open market for generics and biosimilars.
Competitive Positioning
Key Competitors:
- Yaz (Yazmin/Esteva): Contains drospirenone and ethinylestradiol.
- Microgynon 21/30: Contains levonorgestrel and ethinylestradiol.
- Mercado Locally Available Generics: Numerous local brands utilizing similar formulations.
Differentiation Factors:
- Formulation efficacy and safety profile.
- Brand recognition and marketing.
- Pricing strategies.
- Distribution network and physician prescribing habits.
Financial Fundamentals
Pricing and Revenue:
- Retail price in Brazil: approximately USD 3-4 per cycle.
- Estimated annual sales volume: 10 million cycles in Brazil for OGESTREL, considering market share and growth.
- Revenue estimates: USD 30-40 million annually, assuming sustained market penetration.
Cost Structure:
- Manufacturing costs: estimated at USD 0.50 per cycle.
- Regulatory compliance and distribution: USD 0.25 per cycle.
- Marketing and sales: USD 0.50 per cycle.
Annual gross profit margin: approximately 70%. Operating expenses, including R&D, administrative overhead, and marketing, sum up to roughly USD 5 million annually.
Growth Potential
The market for combined oral contraceptives in Brazil is mature but presents growth opportunities through:
- Brand loyalty and physician-prescribed patterns.
- Possible increases in self-administered contraceptive adoption.
- Expansion into neighboring Latin American markets.
Market shifts favoring low-estrogen formulations could affect demand, but OGESTREL's formulation remains within standard practice.
Risk Factors
- Regulatory changes or price controls by Brazilian authorities.
- Entry of low-cost generics reducing prices.
- Shifts in contraception preferences toward long-acting reversible contraception (LARC).
- Supply chain disruptions affecting production costs and availability.
Summary of Investment Outlook
OGESTREL 0.5/50-28 remains a stable revenue generator within Brazil’s contraceptive market segment. The lack of patent barriers favors generic competition, pressuring margins but also opening opportunities for cost-effective expansion. The product’s moderate market share is sustainable if managed with effective marketing and distribution strategies.
Key Takeaways
- The product’s patent expiration opens market competition; pricing will be key to maintaining sales.
- Brazil’s contraceptive market is mature, requiring targeted growth strategies.
- Cost controls and local regulatory compliance are crucial.
- Expansion into Latin America offers growth potential but requires market-specific strategies.
- Market trends toward LARC may dampen long-term growth but unlikely to eliminate current demand.
FAQs
1. What are the primary factors influencing profitability for OGESTREL in Brazil?
Market share, pricing strategy, production costs, and regulatory compliance.
2. How does the expiration of patents impact OGESTREL's market position?
It opens the market to generics, increasing competition and reducing prices, which can affect margins.
3. Is there potential for OGESTREL to expand into other markets?
Yes; neighboring Latin American countries with similar regulatory environments are potential markets with existing demand.
4. What are the main competitive threats in the oral contraceptive sector?
Generic entrants, shifts to LARC methods, and changes in prescribing habits.
5. What strategic moves could sustain OGESTREL’s market position?
Brand reinforcement, cost competitiveness, expanding distribution channels, and market diversification.
References
[1] MarketWatch, "Global Contraceptive Market Size & Trends," 2023.
